All‐cause mortality · women with operable primary breast cancer
Sentinel node biopsy showed no clear difference in all‐cause mortality compared with full axillary surgery (moderate certainty).
1 finding from 1 review
Lymphoedema Patient‐reported lymphoedema of any severity · women with operable primary breast cancer
Sentinel node biopsy may leads to lower lymphoedema Patient‐reported lymphoedema of any severity compared with full axillary surgery (low certainty).
1 finding from 1 review
Subjective arm movement impairment · women with operable primary breast cancer
It is very uncertain whether sentinel node biopsy changes subjective arm movement impairment compared with full axillary surgery (very low certainty).
1 finding from 1 review
Health‐related quality of life (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Anxiety · women with diagnosed breast cancer
1 finding from 1 review
Fatigue · women with diagnosed breast cancer
1 finding from 1 review
Sleep disturbances (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Health‐related quality of life Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Fatigue · women with diagnosed breast cancer
1 finding from 1 review
Health‐related quality of life (medium‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Depression (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Anxiety · women with diagnosed breast cancer
1 finding from 1 review
Fatigue · women with diagnosed breast cancer
2 findings from 1 review
Sleep disturbances (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Health‐related quality of life (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Depression (short‐term) Self‐assessed questionnaires · women with diagnosed breast cancer
1 finding from 1 review
Time to progression · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in time to progression compared with other endocrine treatment (moderate certainty).
1 finding from 1 review
Clinical benefit rate · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in clinical benefit rate compared with other endocrine treatment (high certainty).
1 finding from 1 review
All‐cause mortality · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in mortality compared with other endocrine treatment (high certainty).
1 finding from 1 review
Vasomotor toxicity · women with hormone‐sensitive advanced breast cancer
Fulvestrant showed no clear difference in vasomotor toxicity compared with other endocrine treatment (high certainty).
1 finding from 1 review